A Longitudinal Analysis of Mouth Opening in 1101 Systemic Sclerosis Patients from the French National Cohort Study

Benjamin Chaigne¹, Alexandre Bense², Christian AGARD³, Yannick ALLANORE⁴, Gregory Pugnet⁵, Eric Hachulla⁶, Jérôme Avouac⁷, Boris Bienvenu⁸, Sylvain Palat⁹, Claire Grange¹⁰, Sabine Berthier¹¹, Emmanuel Chatelus¹², sebastien riviere¹¹, Marie-Elise Truchetet¹³, Jean-Emmanuel Kahn¹⁴, Francois Maurier¹⁵, elisabeth diot¹⁶, Alice Berezne¹¹ and Luc Mouthon¹⁷, ¹Paris Cité University, Paris, France, ²APHP, Paris, France, ³Internal medicine, Nantes University Hospital, Nantes, France, ⁴Université Paris Cité, Paris, France, ⁵CHU Toulouse Rangueil Service de Medecine Interne et Immunologie Clinique, Toulouse, France, ⁶University of Lille, Lille, France, ⁷Service de Rhumatologie, Hôpital Cochin, AP-HP.Centre – Université Paris Cité, Paris, France, ⁸Saint Joseph Hospital, Marseille, France, ⁹...., Paris, France, ¹⁰..., Paris, France, ¹¹Internal Medicine - Cochin University Hospital, Paris, France, ¹²Internal Medicine - Cochin University Hospital, Strasbourg, France, ¹³Bordeaux University Hospital, Bordeaux, France, ¹⁴AP-HP, Suresnes Cedex, France, ¹⁵Hôpitaux privés de Metz, Vaux / Frankreich, France, ¹⁶Internal Medicine - Cochin University Hospital, Tours, France, ¹⁷Hopital Cochin - Paris University, Paris, France

Meeting: ACR Convergence 2023

Keywords: Systemic sclerosis

Session Information

Date: Sunday, November 12, 2023

Title: (0609–0672) Systemic Sclerosis & Related Disorders – Clinical Poster I: Research

Session Type: Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: Few studies have evaluated mouth opening (MO) in systemic sclerosis (SSc). None have studied MO trajectories.

Methods: We performed a multicentre study patients enrolled in the French national SSc cohort with at least one MO assessment, described patients based on MO baseline measure, modelized MO trajectories, and associated MO measures with SSc prognosis.

Results: 1101 patients were included in the study. Baseline MO was associated with disease severity. Kaplan Meier analysis showed that MO < 30mm was associated with a worse 30-year-survival (p< 0.01) and higher risk of pulmonary arterial hypertension occurrence (p< 0.05). Individual MO trajectories were heterogenous between patients. The best model of MO trajectories using latent process mixed models showed that 88.8% patients had a stable MO trajectory, and clustered patients into 3 groups which were predictive of SSc survival (p< 0.05). and interstitial lung disease (ILD) (p< 0.05). It highlighted a cluster of 9.5% patients with diffuse SSc (dcSSc) (p< 0.05) and a high but decreasing MO over one year (p< 0.0001) at higher risk of a poor survival and ILD occurrence.

Conclusion: MO, which is a simple and reliable measure, is predictive of disease severity and survival in SSc. Although it remains stable in most SSc patients, dcSSc patients with high but decreasing MO are at risk of poor survival and ILD occurrence.

Disclosures: B. Chaigne: None; A. Bense: None; C. AGARD: None; Y. ALLANORE: AbbVie/Abbott, 2, Alpine Immunoscience, 5, AstraZeneca, 2, Bayer, 2, Boehringer-Ingelheim, 2, Janssen, 2, Medsenic, 2, 5, Mylan, 2, OSE Immunotherapeutics, 5, Prometeus, 2, Roche, 2, Sanofi, 2; G. Pugnet: None; E. Hachulla: Bayer, 2, CSL Behring, 5, GlaxoSmithKlein(GSK), 2, 5, 6, johnson&Johnson, 2, 5, 6, Novartis, 2, 5, Otsuka, 6, Roche-Chugai, 2, 5, 6, sanofi-genzyme, 2, 5, Sobi, 5; J. Avouac: AbbVie, 6, AstraZeneca, 6, Biogen, 6, BMS, 5, 6, Fresenius Kabi, 5, 6, Galapagos, 5, 6, Janssen, 6, Lilly, 6, Medac, 6, MSD, 6, Nordic Pharma, 6, Novartis, 6, Novartis (Dreamer), 5, Pfizer, 6, Pfizer (Passerelle), 5, Roche-Chugai, 6, Sandoz, 6, Sanofi, 6; B. Bienvenu: None; S. Palat: None; C. Grange: None; S. Berthier: None; E. Chatelus: None; s. riviere: None; M. Truchetet: AbbVie/Abbott, 2, 6, Boehringer-Ingelheim, 2, 6, Gilead, 5, 6, Merck/MSD, 6, UCB, 6, 12, support for conferences; J. Kahn: None; F. Maurier: None; e. diot: None; A. Berezne: None; L. Mouthon: None.

To cite this abstract in AMA style:

Chaigne B, Bense A, AGARD C, ALLANORE Y, Pugnet G, Hachulla E, Avouac J, Bienvenu B, Palat S, Grange C, Berthier S, Chatelus E, riviere s, Truchetet M, Kahn J, Maurier F, diot e, Berezne A, Mouthon L. A Longitudinal Analysis of Mouth Opening in 1101 Systemic Sclerosis Patients from the French National Cohort Study [abstract]. Arthritis Rheumatol. 2023; 75 (suppl 9). https://acrabstracts.org/abstract/a-longitudinal-analysis-of-mouth-opening-in-1101-systemic-sclerosis-patients-from-the-french-national-cohort-study/. Accessed .

« Back to ACR Convergence 2023

ACR Meeting Abstracts - https://acrabstracts.org/abstract/a-longitudinal-analysis-of-mouth-opening-in-1101-systemic-sclerosis-patients-from-the-french-national-cohort-study/